These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18090742)

  • 1. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
    Park JW; Qi WN; Cai Y; Urbaniak JR; Chen LE
    Plast Reconstr Surg; 2007 Dec; 120(7):1808-1818. PubMed ID: 18090742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.
    Chen FT; Yang CM; Yang CH
    PLoS One; 2013; 8(5):e64262. PubMed ID: 23691186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.
    Park JW; Kim KM; Oh KJ; Rhyu IJ; Jang HS
    J Trauma; 2009 Mar; 66(3):743-8. PubMed ID: 19276748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
    An J; Sun Y; Fisher M; Rettig MB
    Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
    Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
    Lu SF; Lu H; Shen WY; Zhang JF; Liu P; Wang YR; Wang LX; Yang H; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1006-9. PubMed ID: 18928584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib attenuates murine collagen-induced arthritis.
    Lee SW; Kim JH; Park YB; Lee SK
    Ann Rheum Dis; 2009 Nov; 68(11):1761-7. PubMed ID: 19054826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
    Zhao WL; Liu YY; Zhang QL; Wang L; Leboeuf C; Zhang YW; Ma J; Garcia JF; Song YP; Li JM; Shen ZX; Chen Z; Janin A; Chen SJ
    Blood; 2008 Apr; 111(7):3867-71. PubMed ID: 18235046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramural delivery of bortezomib inhibits restenosis following arterial injury.
    Gong X; Zhou Y
    Vasa; 2011 Nov; 40(6):449-52. PubMed ID: 22090177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
    Zhang L; Zhang ZG; Liu X; Hozeska A; Stagliano N; Riordan W; Lu M; Chopp M
    Thromb Haemost; 2006 Jan; 95(1):166-73. PubMed ID: 16543976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-kappaB p65 involves in reperfusion injury and iNOS gene regulation in skeletal muscle.
    Qi WN; Chaiyakit P; Cai Y; Allen DM; Chen LE; Seaber AV; Urbaniak JR
    Microsurgery; 2004; 24(4):316-23. PubMed ID: 15274191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control.
    Marfella R; Di Filippo C; Portoghese M; Siniscalchi M; Martis S; Ferraraccio F; Guastafierro S; Nicoletti G; Barbieri M; Coppola A; Rossi F; Paolisso G; D'Amico M
    Cardiovasc Pathol; 2009; 18(6):332-45. PubMed ID: 19144543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
    Schmidt N; Gonzalez E; Visekruna A; Kühl AA; Loddenkemper C; Mollenkopf H; Kaufmann SH; Steinhoff U; Joeris T
    Gut; 2010 Jul; 59(7):896-906. PubMed ID: 20581238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischemia-reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation.
    Ramachandran S; Liaw JM; Jia J; Glasgow SC; Liu W; Csontos K; Upadhya GA; Mohanakumar T; Chapman WC
    Transpl Immunol; 2012 Jun; 26(4):201-6. PubMed ID: 22286145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome: an emerging target for cancer therapy.
    Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
    Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition in cancer: development of PS-341.
    Adams J
    Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.